Insomnia
291 results
201 - 291
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia- Opioid antagonists with minimal sedation for opioid withdrawal
- Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome
- Behavioural therapies versus other psychological therapies for depression
- Green tea (Camellia sinensis) for the prevention of cancer
- 'Third wave' cognitive and behavioural therapies versus treatment as usual for depression: Cochrane systematic review
- Nasal decongestants for the common cold: Cochrane systematic review
- Ganoderma lucidum (Reishi mushroom) for cancer treatment
- Cognitive behavioural interventions for sleep problems in adults aged 60+
Honey for acute cough in children - Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
- Effects of opioid, hypnotic and sedating medications on sleep‐disordered breathing in adults with obstructive sleep apnoea
Treating opioid use disorder in primary care—limited data, but looks feasible- Cholinesterase inhibitors for mild cognitive impairment
- Interventions for treating acute high altitude illness: Cochrane systematic review
- Home-based multidimensional survivorship programmes for breast cancer survivors: Cochrane systematic review
- Adrenergic drugs for urinary incontinence in adults: Cochrane systematic review
- Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
- Smoking cessation
- Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
- Adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications
- Peer support for people with schizophrenia or other serious mental illness
- S‐adenosyl methionine (SAMe) for depression in adults
- Second‐generation antidepressants for preventing seasonal affective disorder in adults
- Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain
- Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
- Selective serotonin re‐uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)
- Antivirals for idiopathic sudden sensorineural hearing loss: Cochrane systematic review
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
- Depression in adolescents
- Memory complaints, mild cognitive impairment and dementia
- Pharmacological treatment of depression
- Interventions for chronic pruritus of unknown origin
- Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
- Telerehabilitation for persons with multiple sclerosis
- Aripiprazole versus placebo for schizophrenia: Cochrane systematic review
- Oral budesonide for induction of remission in ulcerative colitis
- Mental disorders due to somatic disease
- Drug therapy for preventing post‐dural puncture headache
- Therapeutic drug monitoring of antiretrovirals for people with HIV
- Laquinimod for multiple sclerosis: Cochrane systematic review
- Acupuncture
- Oral budesonide for induction of remission in ulcerative colitis
- Risperidone versus olanzapine for schizophrenia
- Adjuvant therapy with antidepressants for the management of inflammatory bowel disease: Cochrane systematic review
- Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders
- Budesonide for maintenance of remission in Crohn's disease
- Seasonal affective disorder (SAD)
- Oestrogen and combined oestrogen/progestogen replacement therapy for hot flushes
- Short‐course oral steroids as an adjunct therapy for chronic rhinosinusitis
- Ginkgo biloba for tinnitus
- Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome
- Psychosocial interventions for benzodiazepine harmful use, abuse or dependence
- Pharmacotherapy for sleep bruxism
- Acupuncture for schizophrenia
- Honey for acute cough in children
- Fluvoxamine for the treatment of COVID‐19
- Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder
- Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications: Cochrane systematic review
- Antidepressants for people with epilepsy and depression
- Systemic and topical antibiotics for chronic rhinosinusitis
- Sound therapy (using amplification devices and/or sound generators) for tinnitus
- Placebo interventions for all clinical conditions: Cochrane systematic review
- Approaches for discontinuation versus continuation of long‐term antidepressant use for depressive and anxiety disorders in adults
- Antidepressants for the treatment of depression in people with cancer
- Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
- Antidepressants plus benzodiazepines for adults with major depression
- Pharmacotherapies for sleep disturbances in dementia
- Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies: Cochrane systematic review
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
- Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD)
- Lifestyle education in type 2 diabetes
- Neuromodulators for pain management in rheumatoid arthritis
- Varenicline and bupropion and suicidal behaviour
- Functional bowel disorders and the irritable bowel syndrome (IBS)
- Use of medication during pregnancy